Fresenius Kabi (www.fresenius-kabi.com) is a leading global health care company that focuses on medicines and medical devices used to care for critically and chronically ill patients. Our products include intravenous specialty and generic medicines, infusion therapies, blood-transfusion technologies and clinical nutrition. Our roots go back more than 100 years to the founding of our parent company, Fresenius SE, in Bad Homburg, Germany, where the company is headquartered today. In the United States, Fresenius Kabi offers a broad portfolio of specialty and generic pharmaceuticals under the APP brand (www.APPpharma.com). In 2012, Fresenius Kabi acquired Fenwal Inc. (www.fenwalinc.com), expanding the Fresenius Kabi offering to include Fenwal products for transfusion medicine. These include advanced medical technologies used in blood separation, collection, filtration, storage and transfusion. Fenwal, Inc., a Fresenius Kabi company, is a global blood technology company dedicated to supporting transfusion medicine and cell therapies. We help ensure the availability, safety, and effectiveness of treatments that depend on blood – medicine’s most vital natural resource.